Wer ist hier noch dabei, und erwartet, dass in den nächsten Tagen hoch gehen könnte ?
Top-News
Antisoma
Beiträge:
5
Zugriffe: 1.843 / Heute: 3
Zugriffe: 1.843 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,66%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +68,13%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +52,57%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +49,20%
Xtrackers MSCI Fintech Innovation UCITS ETF 1C
Perf. 12M: +47,31%
Hallo Dan17,
bin schon länger bei Antisoma dabei (seit 30.03.2001). Habe
damals für 2,35 € gekauft, größere Position.
Hab leider kein Stop/Lost gesetzt, naja, jetzt sehe ich ja wo
die Aktie steht.
Was machen, verkaufen mit richtig Verlust oder stehen lassen
und abwarten.
Ich hab aber auch schon ewig keine News von Antisoma gelesen
oder gehört, weißt Du etwas über den neuerlichen Absturz heute.
bin schon länger bei Antisoma dabei (seit 30.03.2001). Habe
damals für 2,35 € gekauft, größere Position.
Hab leider kein Stop/Lost gesetzt, naja, jetzt sehe ich ja wo
die Aktie steht.
Was machen, verkaufen mit richtig Verlust oder stehen lassen
und abwarten.
Ich hab aber auch schon ewig keine News von Antisoma gelesen
oder gehört, weißt Du etwas über den neuerlichen Absturz heute.
Also 12- Monatskursziel mindestens 2 €
ANTISOMA:
21 January 2002, London, UK - Antisoma plc (LSE:ASM, NASDAQ-Europe:ASOM),
the UK-based biopharmaceutical company specialising in the development of
drugs to treat cancer, today announces positive pre-clinical results for
the treatment of solid tumours with DMXAA when used in combination with
chemotherapy agents.
The studies were undertaken by the University of Auckland, New Zealand, to
examine the effect of combining a single dose of DMXAA with single doses of
nine widely-used chemotherapy agents in solid tumour in vivo models.
Neither DMXAA nor the chemotherapy drugs alone provided prolonged delays in
tumour growth or cures. However, co-administration with DMXAA produced a
significant delay in tumour growth for eight of the nine chemotherapy
drugs. The greatest effect was seen with the chemotherapy agents Taxol®
and Taxotere®. In the combination of DMXAA with Taxol®, a median tumour
growth delay of 29.5 days was observed and four of the eleven mice treated
were cured. The dose of Taxol® used, which was less than the maximum
tolerated dose, by itself had no significant activity on the tumour with a
median tumour growth delay of 0.3 days and no cures. In the group treated
with DMXAA alone, a median growth delay of 10 days was seen and one of the
seven mice treated was cured.
In the light of these findings, Antisoma plans to start a clinical study
with DMXAA in combination with chemotherapy by the end of this year,
following completion of a small dose-finding study in patients.
DMXAA is a small molecule that selectively restricts the blood flow through
existing tumour blood vessels that feed tumour growth. DMXAA also appears
to cause the endothelial cells lining the blood vessels to release
substances that may sensitise tumours to chemotherapeutic agents. The
product has already completed two Phase I studies where it was given by
itself. It is Antisoma`s intention to develop DMXAA in combination with
chemotherapy for a variety of different solid tumours.
Commenting on the results, Glyn Edwards, Chief Executive Officer of
Antisoma, said: "These highly encouraging results show that DMXAA has the
potential to improve the efficacy of cancer treatment when used in
combination with many of today`s chemotherapy regimes. We believe that
this drug may have a significant market potential in the treatment of a
wide variety of solid tumours."
Enquiries:
Antisoma plc
Glyn Edwards, Chief Executive Officer Tel: +44 (0)20 8799 8200
Financial Dynamics
Melanie Toyne-Sewell Tel: +44 (0)20 7831 3113
Except for the historical information presented, certain matters discussed
in this statement are forward looking statements that are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from results, performance or achievements expressed or implied
by such statements. These risks and uncertainties may be associated with
product discovery and development, including statements regarding the
company`s clinical development programmes, the expected timing of clinical
trials and regulatory filings. Such statements are based on management`s
current expectations, but actual results may differ materially.
Notes to Editors
Antisoma
Antisoma is a biopharmaceutical company developing novel products for the
treatment of cancer. Using its drug development experience, the Company
aims to produce safer and more effective tumour targeting therapies for
commercialisation by pharmaceutical partners. Antisoma acquires the rights
to promising new product candidates through partnerships with
internationally recognised academic or cancer research institutions. These
include the lead product candidate, pemtumomab, which was licensed from the
Imperial Cancer Research Fund and is currently in a Phase III study as
adjuvant treatment for ovarian cancer, with designated Orphan Drug status
in the US and EU. There are three additional products in the clinical
pipeline, Therex, DMXAA and TheraFab, and several pre-clinical programmes
of which two, Angiomab and Thioplatin, are expected to enter clinical
studies in 2002. Visit www.antisoma.com for further information about
Antisoma.
DMXAA
DMXAA was discovered by Professors Bruce Baguley and William Denny and
their teams at the Auckland Cancer Society Research Centre ("ACSRC"),
University of Auckland, New Zealand. Phase I human clinical trials have
provided safety data and indicate that DMXAA causes a reduction in tumour
blood flow when used alone. In extensive studies in animal models, DMXAA
used in combination with a number of other anti-cancer agents ?
particularly taxanes ? has been found to control tumour growth. These
results have been submitted for peer reviewed publication. Antisoma intend
to test DMXAA in combination with chemotherapy.
Cancer Research Ventures (CRV)
DMXAA was in-licensed from Cancer Research Ventures Limited (CRV). CRV is
a technology transfer and development company established by The Cancer
Research Campaign in the UK to provide technology transfer services to
cancer researchers on a worldwide basis. CRV, and its forerunner CRCT,
have been providing these services to UK researchers since 1987 and have
recently expanded the business into Europe and further afield through the
affiliate company Biotech Research Ventures in Singapore. CRV has been
instrumental in establishing a number of successful biotech companies in
the UK.
21 January 2002, London, UK - Antisoma plc (LSE:ASM, NASDAQ-Europe:ASOM),
the UK-based biopharmaceutical company specialising in the development of
drugs to treat cancer, today announces positive pre-clinical results for
the treatment of solid tumours with DMXAA when used in combination with
chemotherapy agents.
The studies were undertaken by the University of Auckland, New Zealand, to
examine the effect of combining a single dose of DMXAA with single doses of
nine widely-used chemotherapy agents in solid tumour in vivo models.
Neither DMXAA nor the chemotherapy drugs alone provided prolonged delays in
tumour growth or cures. However, co-administration with DMXAA produced a
significant delay in tumour growth for eight of the nine chemotherapy
drugs. The greatest effect was seen with the chemotherapy agents Taxol®
and Taxotere®. In the combination of DMXAA with Taxol®, a median tumour
growth delay of 29.5 days was observed and four of the eleven mice treated
were cured. The dose of Taxol® used, which was less than the maximum
tolerated dose, by itself had no significant activity on the tumour with a
median tumour growth delay of 0.3 days and no cures. In the group treated
with DMXAA alone, a median growth delay of 10 days was seen and one of the
seven mice treated was cured.
In the light of these findings, Antisoma plans to start a clinical study
with DMXAA in combination with chemotherapy by the end of this year,
following completion of a small dose-finding study in patients.
DMXAA is a small molecule that selectively restricts the blood flow through
existing tumour blood vessels that feed tumour growth. DMXAA also appears
to cause the endothelial cells lining the blood vessels to release
substances that may sensitise tumours to chemotherapeutic agents. The
product has already completed two Phase I studies where it was given by
itself. It is Antisoma`s intention to develop DMXAA in combination with
chemotherapy for a variety of different solid tumours.
Commenting on the results, Glyn Edwards, Chief Executive Officer of
Antisoma, said: "These highly encouraging results show that DMXAA has the
potential to improve the efficacy of cancer treatment when used in
combination with many of today`s chemotherapy regimes. We believe that
this drug may have a significant market potential in the treatment of a
wide variety of solid tumours."
Enquiries:
Antisoma plc
Glyn Edwards, Chief Executive Officer Tel: +44 (0)20 8799 8200
Financial Dynamics
Melanie Toyne-Sewell Tel: +44 (0)20 7831 3113
Except for the historical information presented, certain matters discussed
in this statement are forward looking statements that are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from results, performance or achievements expressed or implied
by such statements. These risks and uncertainties may be associated with
product discovery and development, including statements regarding the
company`s clinical development programmes, the expected timing of clinical
trials and regulatory filings. Such statements are based on management`s
current expectations, but actual results may differ materially.
Notes to Editors
Antisoma
Antisoma is a biopharmaceutical company developing novel products for the
treatment of cancer. Using its drug development experience, the Company
aims to produce safer and more effective tumour targeting therapies for
commercialisation by pharmaceutical partners. Antisoma acquires the rights
to promising new product candidates through partnerships with
internationally recognised academic or cancer research institutions. These
include the lead product candidate, pemtumomab, which was licensed from the
Imperial Cancer Research Fund and is currently in a Phase III study as
adjuvant treatment for ovarian cancer, with designated Orphan Drug status
in the US and EU. There are three additional products in the clinical
pipeline, Therex, DMXAA and TheraFab, and several pre-clinical programmes
of which two, Angiomab and Thioplatin, are expected to enter clinical
studies in 2002. Visit www.antisoma.com for further information about
Antisoma.
DMXAA
DMXAA was discovered by Professors Bruce Baguley and William Denny and
their teams at the Auckland Cancer Society Research Centre ("ACSRC"),
University of Auckland, New Zealand. Phase I human clinical trials have
provided safety data and indicate that DMXAA causes a reduction in tumour
blood flow when used alone. In extensive studies in animal models, DMXAA
used in combination with a number of other anti-cancer agents ?
particularly taxanes ? has been found to control tumour growth. These
results have been submitted for peer reviewed publication. Antisoma intend
to test DMXAA in combination with chemotherapy.
Cancer Research Ventures (CRV)
DMXAA was in-licensed from Cancer Research Ventures Limited (CRV). CRV is
a technology transfer and development company established by The Cancer
Research Campaign in the UK to provide technology transfer services to
cancer researchers on a worldwide basis. CRV, and its forerunner CRCT,
have been providing these services to UK researchers since 1987 and have
recently expanded the business into Europe and further afield through the
affiliate company Biotech Research Ventures in Singapore. CRV has been
instrumental in establishing a number of successful biotech companies in
the UK.
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Sarossa Capital Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
10 | 993 | Antisoma zu alten Höhen ? | DonCarlo | stumpfpft | 25.04.21 01:33 | |
| 9 | Sarossa Capital 2015 | paradiswelt | profi108 | 25.04.21 00:49 | ||
| 4 | 185 | Bald geht los !!!! | maulaffe | MiamiFrank | 04.06.10 14:04 | |
| 186 | Neubewertung | esperanto | kalleari | 29.03.10 18:27 | ||
| 1 | Healthcare Conference | kalleari | kalleari | 16.09.09 19:55 |
